This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Suxamethonium

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Suxamethonium is a depolarising neuromuscular blocker producing a rapid (1-2 minutes), complete and predictable relaxation of skeletal muscle. Its effect normally lasts 3-5 minutes. It is used for emergency intubation - passage of endotracheal tube.

It has many side-effects or rare complications:

  • arrhythmias
  • bradycardia:
    • especially in children after repeated use
    • requires a dose of atropine before administration of a second injection in the same patient
  • hyperkalaemia:
    • 0.5-1.0 mmol/l rise in plasma potassium
    • dangerous rises reported in certain cases, e.g. burns, rhabdomyolysis
  • increased intraocular pressure
  • increased salivation
  • myotonia
  • painful fasciculation on injection - give after start of induction
  • anaphylaxis
  • malignant hyperthermia
  • rarely, atypical pseudocholinesterase enzyme results in slow breakdown of suxamethonium; blockade may last for hours

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.